.png)
Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- Dec 8
- 1 min read
Updated: Dec 10
07/12/2025
In Ph3 trial, Lilly's Jaypirca met its primary endpoint of ORR in CLL/SLL (Ref)
The Phase 3 BRUIN CLL-314 trial of Eli Lilly and Company's pirtobrutinib (Jaypirca; BTK inhibitor) met its primary endpoint of non-inferiority on ORR vs ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve or were BTK inhibitor-naïve.
ORR: 87.0% [95% CI, 82.90-90.44] vs 78.5% [95% CI, 73.73-82.85]; p<0.0001
While immature, PFS was also trending in favor of pirtobrutinib vs ibrutinib across all populations, including HR of 0.239 [95% CI, 0.098-0.586] in treatment-naïve patients, the subgroup with the longest follow-up
Comments